Haibo Li

555 citations
32 papers · 405 indexed · h-index 12
Topics
Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers)Hepatocellular Carcinoma Treatment and Prognosis (4 papers)Liver Disease Diagnosis and Treatment (4 papers)
Partner nations
ChinaUnited StatesCanada

In The Last Decade

Haibo Li

30 papers receiving 397 citations

Peers

Haibo Li
Comparison fields: 5 of 89
  • Surgery 171
  • Pathology and Forensic Medicine 91
  • Oncology 51
  • Epidemiology 45
  • Molecular Biology 44
Replace Liqun Pan with:
Liqun Pan China
Jia‐Feng Chen Taiwan
Guangqi Chang China
Gennyne Walker United States
Julia Kurz Germany
Wu Ji China
Dapeng Jiang China
Kyung-Soo Kim South Korea
Stacey S. Kelpke United States
Rosy Eloy France
Haibo Li relative to Liqun Pan China Liqun Pan's profile →
Citations per field
00.5×3.9×
Liqun Pan · 1×
Citations per year

Countries citing papers authored by Haibo Li

Since Specialization
Citations

This map shows the geographic impact of Haibo Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haibo Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haibo Li more than expected).

Fields of papers citing papers by Haibo Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haibo Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haibo Li. The network helps show where Haibo Li may publish in the future.

Co-authorship network of co-authors of Haibo Li

This figure shows the co-authorship network connecting the top 25 collaborators of Haibo Li. A scholar is included among the top collaborators of Haibo Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haibo Li. Haibo Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 0
4 6
5 3
6 16
7 9
8 6
9 12
10 3
11 6
12 2
13 36
14 18
15 34
16
Hypoxia-inducible factor 1 alpha contributes to pulmonary vascular dysfunction in lung ischemia-reperfusion injury.
16
17 12
18 16
19 29
20 51

About Haibo Li

Haibo Li is a scholar working on Hepatology, Nephrology and Endocrinology, Diabetes and Metabolism, having authored 32 papers that have together received 405 indexed citations. Recurring topics across this work include Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). The work is most often cited by research in Pathology and Forensic Medicine (91 citations), Hepatology (35 citations) and Ophthalmology (39 citations). Haibo Li has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Dongzhi Yang, Jun Nie, Gang Chen, Weishan Chen, Qixin Chen, Jinliang Yang, Rui Niu, Jing Zhang, Gang Shen and Hua Jiang. Their work appears in journals such as Journal of Biological Chemistry, Carbohydrate Polymers and Biochemical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026